Nexalin Technology, Inc. (NXL) vs Catheter Precision, Inc. (VTAK)

Nexalin Technology, Inc. and Catheter Precision, Inc. are both Medical Devices companies. Nexalin Technology, Inc. is the larger, with a market value of $3.6M against $3.0M — 1.2× the size. Catheter Precision, Inc. grew revenue faster over the last twelve months: 219.2% against 24.3%. Catheter Precision, Inc. has the higher net margin (−711.5% vs −4,138.5%) and the higher return on invested capital (−64.4% vs −1,108.8%). Across the 18 metrics below, Catheter Precision, Inc. leads on 13 and Nexalin Technology, Inc. on 5.

Valuation

Metric NXL VTAK Medical Devices median
P/E n/m n/m 22.18
P/S 14.23 0.22 2.70
P/B 2.03 0.02 2.46
Price to free cash flow n/m n/m 22.53
EV/EBITDA n/m n/m 11.78
EV/Sales 9.62 1.00 2.38
Earnings yield (328.35%) (4,593.33%) (8.22%)
Free cash flow yield (205.04%) (2,257.96%) (7.80%)

Profitability

Metric NXL VTAK Medical Devices median
Gross margin 86.14% 47.73% 56.01%
Operating margin (4,201.66%) (1,000.26%) (15.03%)
Net margin (4,138.49%) (711.49%) (20.40%)
Free cash flow margin (2,917.96%) (489.45%) (7.24%)
Return on equity (240.25%) (115.04%) (15.32%)
Return on assets (187.89%) (43.65%) (19.72%)
Return on invested capital (1,108.82%) (64.41%) (10.33%)

Growth

Metric NXL VTAK Medical Devices median
Revenue growth (TTM) 24.26% 219.17% 8.80%
EPS growth (last fiscal year) 39.76% 87.48% —
Revenue growth, 5-year CAGR 4.42% 25.89% 15.23%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NXL VTAK Medical Devices median
Debt to equity 0.00 0.19 0.07
Current ratio 1.25 0.19 2.50
Net debt to EBITDA 0.44 (0.16) 0.49

Dividend

Metric NXL VTAK Medical Devices median
Dividend yield — — 0.94%
Payout ratio — 0.00 0.00

Size

Metric NXL VTAK Medical Devices median
Market cap 3.61m 2.99m 172.91m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack